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Abstract
As the burden of liver disease reaches epidemic levels, there is a high unmet medical need
to develop robust, accurate and reproducible non-invasive methods to quantify liver tissue
characteristics for use in clinical development and ultimately in clinical practice. This pro-
spective cross-sectional study systematically examines the repeatability and reproducibility
of iron-corrected T1 (cT1), T2*, and hepatic proton density fat fraction (PDFF) quantification
with multiparametric MRI across different field strengths, scanner manufacturers and mod-
els. 61 adult participants with mixed liver disease aetiology and those without any history of
liver disease underwent multiparametric MRI on combinations of 5 scanner models from
two manufacturers (Siemens and Philips) at different field strengths (1.5T and 3T). We
report high repeatability and reproducibility across different field strengths, manufacturers,
and scanner models in standardized cT1 (repeatability CoV: 1.7%, bias -7.5ms, 95% LoA of
-53.6 ms to 38.5 ms; reproducibility CoV 3.3%, bias 6.5 ms, 95% LoA of -76.3 to 89.2 ms)
and T2* (repeatability CoV: 5.5%, bias -0.18 ms, 95% LoA -5.41 to 5.05 ms; reproducibility
CoV 6.6%, bias -1.7 ms, 95% LoA -6.61 to 3.15 ms) in human measurements. PDFF repeat-
ability (0.8%) and reproducibility (0.75%) coefficients showed high precision of this metric.
Similar precision was observed in phantom measurements. Inspection of the ICC model
indicated that most of the variance in cT1 could be accounted for by study participants
(ICC = 0.91), with minimal contribution from technical differences. We demonstrate that mul-
tiparametric MRI is a non-invasive, repeatable and reproducible method for quantifying liver
tissue characteristics across manufacturers (Philips and Siemens) and field strengths (1.5T
and 3T).







Citation: Bachtiar V, Kelly MD, Wilman HR, Jacobs
J, Newbould R, Kelly CJ, et al. (2019) Repeatability
and reproducibility of multiparametric magnetic
resonance imaging of the liver. PLoS ONE 14(4):
e0214921. https://doi.org/10.1371/journal.
pone.0214921
Editor: Peter Lundberg, Linko¨ping University,
SWEDEN
Received: June 11, 2018
Accepted: March 24, 2019
Published: April 10, 2019
Copyright: © 2019 Bachtiar et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The minimal
anonymised data set has been uploaded to the
Open Science Framework repository: URL: https://
osf.io/68a9g/ DOI: 10.17605/OSF.IO/68A9G.
Funding: The study was funded by Perspectum
Diagnostics. The funder provided support in the
form of salaries for authors V.B., M.D.K., J.J., R.N.,
C.J.K., M.L.G., K.E.G., A.M., A.H.H., C.C.F., M.H.,
M.M., N.J., S.L., and R.B., but did not have any
additional role in the study design, data collection
and analysis, decision to publish, or preparation of
Introduction
As the burden of non-alcoholic fatty liver disease (NAFLD) reaches epidemic levels in devel-
oped countries [1], [2], there is a pressing need to develop non-invasive, standardised, and
quantitative methods [3]. Liver biopsy has long been the gold standard for staging liver disease,
yet it is painful, prone to sampling variability [4], has poor inter-observer concordance [5] and
carries a risk of complications [6]. Magnetic Resonance Imaging (MRI)-based methods are
attractive as they are sensitive to subtle differences in tissue composition, can sample the entire
liver, and yield objective quantitative measurements that can contribute to prospective patient
management [7]–[9].
Multiparametric MRI is a safe and non-invasive method for quantification of liver tissue
characteristics. Images for quantification of hepatic fat from proton density fat fraction
(PDFF) maps, T2�, and iron-corrected T1 (cT1) can be rapidly obtained during abdominal
breath-hold acquisitions without the need for contrast agents or additional external hardware
[8], [10]. Iron correction of T1 (cT1) is necessary to address the confounding effects of excess
iron, which is common in chronic liver disease. Liver MultiScan (LMS, Perspectum Diagnos-
tics, Oxford, UK) is a software application that can be used with supported MR-systems to cor-
rect T1 for the effects of excess iron, and thus, to calculate cT1 from T1 and T2� maps, and
standardise to a 3T field strength [10]. This method has been shown to have high diagnostic
accuracy for the assessment of liver fibrosis compared to histology [8], predict clinical out-
comes in patients with mixed liver disease aetiology [7], identify patients with non-alcoholic
steatohepatitis (NASH) and cirrhosis [9], reliably excludes clinically significant liver disease
with superior negative predictive value (83.3%) to liver stiffness (42.9%) and is cost-effective in
diagnosing NAFLD [11], [12]. Additionally, a recent two-centre study showed excellent test-
retest reliability for multiparametric MRI derived metrics (CoV range of 1.4% to 2.8% for cT1)
in 22 healthy volunteers [13], indicating good technical precision of this method.
The reliability, or precision of metrics are defined as the extent to which measurements can
be reproduced under different conditions such as different scanner field strengths, manufac-
turers, and models (reproducibility), and reflects the degree of agreement between repeated
measurements under identical or near-identical conditions (scan-rescan repeatability) [14].
To be clinically useful, metrics also need to be effective in measuring the heterogeneity of phys-
iological and pathological values in the population [15]. The ability to standardise a measure-
ment across different MR scanner field strengths, manufacturers and models is particularly
relevant in the context of clinical practice and multi-site clinical trials.
The purpose of this study was to systematically test the repeatability, reproducibility, and
intra- and inter-operator reliability of cT1, T2�, and PDFF measurements across scanner field
strength, manufacturer, and model in human participants and phantoms. The performance of
T1-mapping standardisation was also evaluated in phantoms.
Materials and methods
Study design and population
Sixty-one participants (aged 22–80, mean 42 years; 25 males; BMI 18–39, mean 25) gave their
written informed consent to participate. This study received ethical approval from the South
Central Oxford Research Ethics Committee C (Ref: 17/SC/0205). Participants included those
with mixed liver disease aetiology (n = 32) and those without any history of liver disease
(n = 29) in order to represent a wide range of values of hepatic fat, iron, and fibro-inflamma-
tory status. Exclusion criteria included the presence of MRI contraindications and the inability
to obtain informed consent. MR operators and data analysts were blinded to the indication of
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participants with liver disease and those without. All participants underwent two serial multi-
parametric MRI examinations per scanner on at least two different scanners in pseudorando-
mised order (Fig 1). Same scanner scan-rescan were done on the same day and the time
between different scanners ranged from same-day up to 1 week. Participants were instructed
to take nothing by mouth for 4 hours before their scan time.
Phantom multiparametric MRI
Phantoms were manufactured to span the normal and clinically relevant range of values
expected in the liver to reflect the heterogeneity within the population of interest [16]. Three
phantoms, each specific to T1, T2�, and PDFF were manufactured. T1 phantoms were agar
gel-based using NiCl2 as the paramagnetic relaxation modifier (range: 338-1075ms at 1.5T and
351-1137ms at 3T). T2� phantoms were aqueous solutions of MnCl2 (range: 3-70ms at 1.5T
and 2-43ms at 3T). PDFF phantoms were peanut oil and agar gel-based (0–100% at 1.5T and
3T) manufactured according to the methods of Hines and colleagues [16] (Sigma-Aldrich,
UK).
Phantoms were scanned on four Siemens (Avantofit 1.5T, E11C, MyoMaps; Prisma 3T,
E11C, MyoMaps; Skyra 3T, E11C, MyoMaps; Siemens Healthineers) and four Philips (Ingenia
1.5T, 5.3.0, CardiacQuant; Ingenia 3T, 5.3.0, CardiacQuant; Achieva 1.5T, R5.3, Cardiac-
Quant; Achieva dStream 1.5T, R5.3, CardiacQuant; Philips Healthcare) scanners. MyoMaps
for Siemens systems and CardiacQuant for Philips systems are commercially available modi-
fied Look-Locker inversion recovery (MOLLI) T1-mapping sequences [17]. All phantom mea-
surements were performed with a simulated ECG triggering at 1 beat/s. Differences in the
MRI sequences used on Siemens and Philips platforms produce systematic differences in fitted
Fig 1. Study design. Two manufacturers (Siemens and Philips) and a range of scanner models were used to systematically test the repeatability and reproducibility of
multiparametric-MRI derived measurements in human participants and phantoms.
https://doi.org/10.1371/journal.pone.0214921.g001
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T1 values. These quantitative differences were resolved by using distinct, separately acquired
phantom measurements to generate linear mapping functions to standardise the values
obtained on one system to those from another at the same nominal magnetic field strength
(1.5T or 3T). All 3T systems were linearly mapped to the Siemens Prisma 3T, and all 1.5T sys-
tems to the Siemens Avantofit 1.5T, defined as the reference scanners, see Supporting Informa-
tion S2 File.
Human multiparametric MRI
All human MR scans were performed with participants lying supine on three Siemens (Avan-
tofit 1.5T, E11C, MyoMaps, OCMR Oxford; Prisma 3T, E11C, MyoMaps, OCMR Oxford;
Skyra 3T, E11C, MyoMaps, Southampton General Hospital, UK; Siemens Healthineers) and
two Philips (Ingenia 1.5T, 5.3.0, CardiacQuant, Leiden University Medical Centre; Ingenia 3T,
5.3.0, CardiacQuant, Leiden University Medical Centre; Philips Healthcare) scanners. Local
radiographers at each imaging centre were trained on the protocol and performed the scans in
this study. Single transverse slices were captured through the centre of the liver through the
porta hepatis. The individual components of the multiparametric MR protocol consist of T1,
T2�, and PDFF-mapping. Full details of the scanning sequences for each scanning platform
can be found in Supporting Information S1 File. Linear mappings to reference scanners were
performed in the same manner as phantoms, as described above. Any bias introduced by ele-
vated iron was removed from the T1-measurements, yielding the iron-corrected T1 (cT1) as
previously described [8], [10]. All human scans on both field strengths used the Siemens
Prisma 3T as the reference scanner.
Image processing
Anonymised MR data were analysed off-site using Liver MultiScan software (Version 2, Per-
spectum Diagnostics, UK). Image analysts were trained in abdominal anatomy and images
with artefacts were referred to a team of experienced MR physicists for evaluation as previously
described [18]. Out of the 138 scans that were completed, 3 scans were unquantifiable due to
acquisition errors and in 7 instances due to problems with the scanner cooling system (unre-
lated to this study and protocol), resulting in a scan success rate of 93%. For each acquisition,
three 15mm diameter circular regions of interest (ROIs) were selected on the transverse cT1,
T2�, and PDFF maps to cover a representative sample of the liver parenchyma. To assess intra-
reader variability, analyst 1 (AN1) re-measured the values for all participants and scan repeats
in a randomised order. The time between re-reads was greater than 1 day. To examine inter-
reader variability, the first read from analyst 1 (AN1) was compared to an independent read
from analyst 2 (AN2). Analysts were blinded to all participant and scanner information.
Statistical analysis
Statistical analyses were carried out using R 3.1.1 [19]. The Bland-Altman method was used to
investigate the repeatability and reproducibility between different scanner models against the
reference scanners for each metric in phantom (T1, T2�, and PDFF) and human (cT1, T2�,
and PDFF) measurements. Repeatability (scan-rescan) was assessed as the closeness of agree-
ment using identical equipment (same scanner field strength, manufacturer, and model).
Reproducibility was assessed as the closeness of agreement under varying circumstances (dif-
ferent scanner field strength, manufacturer, and model), such as would be encountered in a
multi-centre setting. Limits of Agreement were calculated as the mean of the differences plus
and minus 1.96 times the standard deviation of the differences. Repeatability and
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reproducibility coefficients are reported as 1.96 times the standard deviation of the differences.
Mean coefficients of variation are the mean of the coefficients of variation for each individual.
To further interrogate the reliability of the cT1 metric, a Linear Mixed Effects (LME)
approach was implemented using the nlme package [20] in R [19]. LME modelling has been
demonstrated to be a superior method to common alternatives such as repeated measures
ANOVA or simple paired students t-test as it provides greater statistical power and is robust in
the face of missing data [21]. Importantly, LME models for replication data separately and
effectively model variance due to within and between subject factors [15], [22]. To assess the
variance that could be accounted for by each explanatory variable, the intraclass correlation
coefficient (ICC) was calculated to determine the proportion of the total variability in the
observations that is due to the differences between pairs.
Results
Standardisation of phantom measurements
We tested the performance of the standardisation of T1 maps across different scanner field
strengths, manufacturers, and models using phantom measurements. Bland-Altman analysis
of phantom-derived mappings from 90 acquisitions across scanner models and software ver-
sions before and after standardization (Fig 2) showed a clear reduction in bias (1.5T: from
-23ms to -3.1ms; 3T: from -14ms to -7.8ms), tightening of the 95% Limits of Agreement (LoA)
(1.5T: from -66.9ms– 20.4ms, to -24.8ms– 18.6ms; 3T: from -38.1ms– 10.5ms, to -24.8ms–
9.19ms) and a decrease in the mean coefficient of variation (CoV) (1.5T: 1.5% to 0.77%; 3T:
2.9% to 1.1%).
Repeatability and reproducibility of phantom measurements
Standardized T1 from phantom-derived mappings demonstrated high repeatability (CoV
0.16%, bias -0.02 ms, 95% LoA of -4.7 to 4.7 ms) and reproducibility (CoV 1%, bias -4.7 ms,
95% LoA of -25.3 ms to 15.9 ms). T2�-mappings showed good repeatability (CoV 1.1%, bias
0.08 ms, 95% LoA of -0.67 to 0.84 ms) and reproducibility (CoV 3%, bias 0.24ms, 95% LoA of
-1.62ms to 2.1ms). Similarly, PDFF measurements also showed good repeatability (CoV 9.7%,
bias -0.12%, 95% LoA of -1.4 to 1.14%) and reproducibility (CoV 14%, bias 0.16%, 95% LoA of
-4.2% to 4.53%) across different scanner field strengths, manufacturers, and models (Fig 3).
Repeatability and reproducibility of human measurements
Standardized cT1 in participants demonstrated high repeatability (CoV 1.7%, bias -7.5 ms,
95% LoA of -53.6 to 38.5 ms) and reproducibility (CoV 3.3%, bias 6.5 ms, 95% LoA of -76.3 ms
to 89.2 ms) across different scanner field strengths, manufacturers, and models. T2�-mappings
showed good repeatability (CoV 5.5%, bias -0.18 ms, 95% LoA of -5.4 to 5.1 ms) and reproduc-
ibility (CoV 6.6%; bias -1.7ms; 95% LoA of -6.6ms to 3.2 ms). Similarly, PDFF measurements
also showed good repeatability (CoV 14%, bias -0.04%, 95% LoA of -0.84 to 0.76%) and repro-
ducibility (CoV 17%, bias 0.06%, 95% LoA of -0.69 to 0.82%) across different scanner field
strengths, manufacturers, and models (Fig 4).
To interrogate the cT1 metric further, a random-effects model was generated to determine
the variation that could be accounted for by each explanatory variable: scanner type (Avantofit
1.5T, Prisma 3T, Skyra 3T, Ingenia 1.5T, Ingenia 3T), scan repeat (SR1, SR2), analyst (AN1,
AN2), and analysis repeat (AR1, AR2). Inspection of the model indicated that most of the vari-
ance in cT1 could be accounted for by study participants (ICC = 0.91), with minimal
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contribution from the other explanatory variables (scanner type = 0.04, scan repeat = 0.003,
analyst = 0, analysis repeat = 0, residual = 0.05).
Discussion
The primary goal of this study was to systematically test the repeatability and reproducibility
of multiparametric-MRI derived measurements across scanner field strength, manufacturer
and model in human participants and phantoms. We report the overall repeatability and
reproducibility of standardised cT1, T2�, and PDFF measurements.
Fig 2. Phantom T1 Standardisation. Bland-Altman plots demonstrating T1 measurements in phantoms before and after standardisation at (a) 1.5T and (b) 3T.
https://doi.org/10.1371/journal.pone.0214921.g002
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High repeatability and reproducibility was demonstrated in each metric tested. We report a
3.3% CoV in cT1 measurements across different manufacturer, field strength, and scanner
model combinations on 61 participants who had mixed liver disease aetiology as well as those
without any history of liver disease to represent the wide range of physiological values in the
population. Interrogation of the cT1 metric indicated that most of the variance could be
accounted for by study participants (ICC = 0.91), with minimal contributions from scanner
type and scan repeat, further supporting the high reproducibility of this measurement.
In a recent study, Harrison and colleagues [23] reported repeatability of cT1, MR Elastogra-
phy (MRE), and shear-wave ultrasonic elastography (LSM) to reveal CoVs of 3.1%, 11%, and
40% respectively. Similarly, Trout and colleagues [24] reported an average of 10.7% CoV in
liver stiffness measurements across different manufacturer, field strength, and sequence com-
binations on 24 healthy adult volunteers with MRE [24]. However, it is not possible to com-
pare the precision performance of these methods using CoV alone, as the underlying
physiological properties and clinically-relevant dynamic range of the techniques are different,
and in the Trout and colleagues study, subjects with known liver disease were not included.
Hines et al [25] reported that liver stiffness measurements from MRE varied by 8% between
examinations in the same patient performed on the same day, and this increased to 12% when
Fig 3. Repeatability and reproducibility of phantom measurements. Bland-Altman plots from phantom measurements across manufacturer and field strength for (a)
T1, (b) T2�, and (c) PDFF.
https://doi.org/10.1371/journal.pone.0214921.g003
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examined on different days separated by 2–4 weeks. In our study same scanner repeatability
measurements were performed on the same day and reproducibility on different scanners
were performed either on the same day or up to 1-week in between. It is possible that the short
time period between serial examinations may have led to an underestimation of physiological
variability and consequently a narrower cT1 range within subjects, and it is possible that this
may increase with intermediate (e.g. 1 week) and longer (e.g. 6-months) time intervals. Future
investigations could define within-subject variability in cT1 measurements to characterise lon-
gitudinal fluctuations in this metric.
In a recent study, Bane and colleagues [26] tested T1 repeatability and reproducibility in a
T1 phantom across 10 MRI scanners. Using an optimized inversion recovery spin echo tech-
nique, they report a median repeatability CoV of 0.3%, and reproducibility CoV of 8.21% at
1.5T and 5.46% at 3T. One site in that study also ran a MOLLI experiment as in this study; the
repeatability CoV was reported at 0.68% with a standard error of 4.64%.
PDFF has been recognised as the best current metric for a standardised MR-based bio-
marker of tissue fat concentration [27]. A meta-analysis of pooled data collected from 28 pub-
lished studies demonstrated high precision of MR-PDFF across different field strengths,
Fig 4. Repeatability and reproducibility of human multiparametric MRI measurements. Bland-Altman plots from human measurements across manufacturer and
field strength for (a) cT1, (b) T2�, and (c) PDFF.
https://doi.org/10.1371/journal.pone.0214921.g004
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manufacturers and reconstruction methods, with repeatability and reproducibility coefficients
of 2.99% and 4.12% respectively [28]. We report a repeatability coefficient of 0.8% and repro-
ducibility coefficient of 0.75%, indicating excellent precision of this metric, in line with the
literature.
Although we recruited subjects with liver diseases and BMI up to 39, subjects only had liver
fat up to about 18% PDFF. There is a known contribution of liver fat to the T1 measurement
[29] that is strongly dependent on the readout parameters. Good inter-scanner reproducibility
was demonstrated in this population with these parameters with no trend of worse reproduc-
ibility with increasing fat fraction, but it is possible that still higher liver fats would show worse
reproducibility. Acquisition of MOLLI data with a fat suppression technique is only available
on one scanner platform; therefore, similar data could not be taken to measure reproducibility
across platform. Other limitations in this study include biases from more 1.5T than 3T phan-
tom and in-vivo reproducibility data, the choice of reference scanner, and limited Philips data.
Finally, the MOLLI based technique [17] for T1 mapping used here only sampled 1 slice in
each breath-hold. This is a limitation of the readout method, rather than of the technique.
Due to practical limitations, only a small number of participants were evaluated using the
Philips scanners at 1.5T and 3T. Although a more balanced sample size per scanner would
have been preferable, multiple phantom measurements performed across these scanners
showed excellent reproducibility. The ability to standardise across different scanner field
strength, manufacturers, and models, is important in the clinical trial setting where accurate
and consistent evaluation of key outcomes across treatment interventions and patient groups
can be aided by the ability to compare data gathered from multiple sites.
Conclusions
Multiparametric MR-derived metrics, cT1, T2� and PDFF, have good repeatability and repro-
ducibility that can quantify liver tissue characteristics independent of scanner manufacturer
(Philips or Siemens) and field strength (1.5T or 3T). Multiparametric MRI is a non-invasive
method that does not require additional hardware, and can be completed in less than 15-min-
utes, which will have important implications for routine monitoring and assessment of the
liver in clinical practice. The ability to standardize metrics will be important in the clinical trial
settings for evaluating treatment interventions.
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